Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4GU | ISIN: US14147L1089 | Ticker-Symbol: XE7C
Tradegate
27.06.25 | 17:40
2,695 Euro
+0,56 % +0,015
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARDIFF ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CARDIFF ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,6602,72028.06.
2,5952,76027.06.

Aktuelle News zur CARDIFF ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCardiff Oncology, Inc. - 8-K, Current Report1
CARDIFF ONCOLOGY Aktie jetzt für 0€ handeln
DiCardiff Oncology stock initiated at Hold by Jefferies on early data concerns3
DiJefferies stuft Cardiff Oncology-Aktie aufgrund früher Datenbedenken mit "Halten" ein3
17.06.Cardiff Oncology falls after naming new medical chief ahead of key trial readout30
17.06.Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer7
17.06.Cardiff Oncology, Inc. - 8-K, Current Report2
17.06.Cardiff Oncology, Inc.: Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC137- Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development...
► Artikel lesen
02.06.Cardiff Oncology reports positive trial results for breast cancer treatment19
02.06.Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025118- Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate - - The trial evaluated three doses...
► Artikel lesen
09.05.Cardiff Oncology stock target raised to $18 by H.C. Wainwright20
08.05.Cardiff Oncology GAAP EPS of -$0.20 misses by $0.01, revenue of $0.1M beats by $0.01M8
08.05.Cardiff Oncology, Inc. - 10-Q, Quarterly Report7
15.04.Cardiff Oncology, Inc.: Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer176 - Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15...
► Artikel lesen
15.04.Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)201SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
► Artikel lesen
14.04.Piper Sandler raises Cardiff Oncology stock target to $1010
03.04.Lucid Capital Markets sets $14 target on Cardiff Oncology stock8
12.03.Cardiff Oncology Surges 18%55
28.02.Cardiff Oncology stock target raised to $17 at H.C. Wainwright15
27.02.Cardiff Oncology, Inc. Full Year Loss Rises12
27.02.Cardiff Oncology plans mixed shelf offering10
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4